Bell J Simon, Blacker Natalie, Edwards Sue, Frank Oliver, Alderman Christopher P, Karan Lesh, Husband Alan, Rowett Debra
Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia.
Aust Fam Physician. 2012 Mar;41(3):110-8.
Osteoporosis remains undertreated in Australian primary care, with as few as 30% of postmenopausal women with a fracture and 10% of men with osteoporosis receiving pharmacological treatment.
This article presents an overview of the pharmacological management of osteoporosis in older people in the general practice setting.
Lifestyle factors and ensuring adequate calcium and vitamin D intake are important in preventing and treating osteoporosis. Pharmacological treatments are recommended for patients with a minimal trauma fracture, for those aged 70 years or over with a T-score of -3.0 or lower, or for those who are currently taking prolonged high dose corticosteroids and who have a T-score of -1.5 or lower. Bisphosphonates are recommended as first line therapy for established postmenopausal osteoporosis. Medicine selection is guided by patient gender, menopausal status, medical and fracture history, patient preference and eligibility for government subsidy.
在澳大利亚初级医疗保健中，骨质疏松症的治疗仍不充分，仅有30%的绝经后骨折女性和10%的骨质疏松男性接受药物治疗。
本文概述了在全科医疗环境中对老年人骨质疏松症的药物治疗。
生活方式因素以及确保充足的钙和维生素D摄入在预防和治疗骨质疏松症方面很重要。对于发生轻微创伤性骨折的患者、70岁及以上且T值为-3.0或更低的患者，或目前正在长期服用高剂量皮质类固醇且T值为-1.5或更低的患者，建议进行药物治疗。双膦酸盐被推荐作为已确诊的绝经后骨质疏松症的一线治疗药物。药物选择以患者性别、绝经状态、病史和骨折史、患者偏好以及政府补贴资格为指导。
